The biologics market was valued at US$ 254.9 Bn in 2017, and expected to reach US$ 580.5 Bn by 2026 at a CAGR of 9.5 % during the forecast period from 2018 to 2026.
—
Market Insights
Global biologics market exhibits remunerative growth during the projection period from 2018 to 2026 due to presence of around 800 biologics in pipeline. The growth attributed is due to incessant expansion in product portfolio with growing demand for biologics across the globe. Increasing prevalence of chronic diseases, unremitting research and development activities and continuous investment in biologics contribute to the overall market growth. According to World Health Organization (WHO), by 2020 chronic diseases would account for 75% of deaths globally. Cancer, autoimmune diseases, and diabetes contribute above 60% of the overall biologics market. In 2016, about 50% of new molecular entities approved by the FDA were biologics. Continuous development in cellular & gene therapy further catalyzes the market owing to its high efficacy and therapeutic outcome. CAR-T cell therapies are the latest therapies approved by the FDA for oncology indications.
Browse the full report Biologics Market Growth, Future Prospects, and Competitive Analysis, 2018 -2026 report at https://www.credenceresearch.com/report/biologics-market
Cellular & gene therapy to exhibit double digit CAGR during the forecast period
(View this segment on full report)
Oncology segment contribute maximum to the overall growth of biologics market
(View this segment on full report)
Preservation of patent rights along with stringent regulatory policies for biosimilars holds North America in dominant position.
(View this segment on full report)
Dominance of established international players with strong product portfolio makes market penetration difficult for emerging players.
Therapeutic biologics market includes an extensive competitive pool with market presence across geographies, dominated by market leaders such as Roche Holding AG, Merck & Co., Inc., Amgen, Inc. and Novartis AG. Continuous partnerships & acquisitions and presence of established international pioneer’s makes entry difficult for emerging market players. Sanofi S.A. and Celgene Corporation., on 22 January 2018 published the acquisitions of Bioverativ for $11.6 Bn and Juno Therapeutics for $ 9.0 Bn respectively thus expanding their dominance in biologics market. However, a constant requirement for targeted therapies in chronic diseases paves way for new market players with strong pipeline portfolio. Established industrial players make it difficult for new players to enter the market owing to their vast market outreach and extensive networking. For instance, Alexion Pharmaceutical, Inc. a biopharmaceutical firm carries a Zacks Rank #3 as per Zacks Equity Research Analysts. Its blockbuster product Soliris recently was additionally approved (October 2017) by FDA for myasthenia gravis thus boosting its sales. Soliris considered for a net sale of US$ 2.8 Bn in 2016 and is required to attain further growth owing to its label expansion.
Product Segment (2016–2026; US$ Bn)
• Recombinant Therapeutic Proteins
o Monoclonal Antibodies
o Hormones
o Cytokines
o Enzymes
• Blood & Blood components
• Cellular & Gene Therapy
• Vaccines
Disease Segment (2016–2026; US$ Bn)
• Oncology
o Breast Cancer
o Leukemia
o Ovarian Cancer
o Non-Hodgkin Lymphoma
o Prostate Cancer
o Colorectal Cancer
o Others (Bladder Cancer, Lung Cancer, etc.)
• Autoimmune diseases
o Systemic Sclerosis
o Crohn’s Disease
o Rheumatoid arthritis
o Systemic Lupus Erythematous
o Others (Sjogren’s syndrome, multiple sclerosis, pernicious anemia, etc.)
• Diabetes
• Infectious diseases
• Others (cardiovascular diseases, ophthalmic conditions, dermatological diseases, etc.)
ToC:
Chapter 4. Global Biologics Market, by Product, 2016-2026 (US$ Bn)
4.1. Overview
4.2. Recombinant Therapeutic Proteins
4.2.1. Monoclonal Antibodies
4.2.2. Hormones
4.2.3. Cytokines
4.2.4. Enzymes
4.3. Blood & Blood components
4.4. Cellular & Gene Therapy
4.5. Vaccines
Chapter 5. Global Biologics Market, by Disease, 2016-2026 (US$ Bn)
5.1. Overview
5.2. Oncology
5.2.1. Breast Cancer
5.2.2. Leukemia
5.2.3. Ovarian Cancer
5.2.4. Non-Hodgkin Lymphoma
5.2.5. Prostate Cancer
5.2.6. Colorectal Cancer
5.2.7. Others (bladder cancer, lung cancer, etc.)
5.3. Autoimmune diseases
5.3.1. Systemic Sclerosis
5.3.2. Crohn’s Disease
5.3.3. Rheumatoid arthritis
5.3.4. Systemic Lupus Erythematous
5.3.5. Others (Sjogren’s syndrome, multiple sclerosis, pernicious anemia, etc.)
5.4. Diabetes
5.5. Infectious diseases
5.6. Others (cardiovascular diseases, ophthalmic conditions, dermatological diseases, etc.)
Chapter 6. Global Biologics Market, by Geography, 2016-2026 (US$ Bn)
6.1. Overview
6.2. North America Biologics Market, 2016-2026 (US$ Bn)
6.2.1. North America Biologics Market, by Product, 2016-2026 (US$ Bn)
6.2.2. North America Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.2.3. North America Biologics Market, by Country, 2016-2026 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Biologics Market, 2016-2026 (US$ Bn)
6.3.1. Europe Biologics Market, by Product, 2016-2026 (US$ Bn)
6.3.2. Europe Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.3.3. Europe Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Biologics Market, 2016-2026 (US$ Bn)
6.4.1. Asia Pacific Biologics Market, by Product, 2016-2026 (US$ Bn)
6.4.2. Asia Pacific Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.4.3. Asia Pacific Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of Asia Pacific
6.5. Latin America Biologics Market, 2016-2026 (US$ Bn)
6.5.1. Latin America Biologics Market, by Product, 2016-2026 (US$ Bn)
6.5.2. Latin America Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.5.3. Latin America Biologics Market, by Country, 2016-2026 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Biologics Market, 2016-2026 (US$ Bn)
6.6.1. Middle East & Africa (MEA) Biologics Market, by Product, 2016-2026 (US$ Bn)
6.6.2. Middle East & Africa (MEA) Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.6.3. Middle East & Africa (MEA) Biologics Market, by Region, 2016-2026 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA
Chapter 7. Company Profiles
7.1. Merck & Co. Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. AbbVie, Inc.
7.3. AstraZeneca Plc.
7.4. Amgen, Inc.
7.5. Celgene Corporation
7.6. Bristol-Myers Squibb Co.
7.7. Eli Lilly and Company
7.8. Janssen Pharmaceuticals, Inc.
7.9. GlaxoSmithKline Plc.
7.10. Novartis AG
7.11. Pfizer, Inc.
7.12. Novo Nordisk A/S
7.13. Sanofi S.A
7.14. Roche Holding AG
7.15. Takeda Pharmaceutical Co., Ltd
………..so on
Browse the full report Biologics Market Growth, Future Prospects, and Competitive Analysis, 2018 -2026 report at https://www.credenceresearch.com/report/biologics-market
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
Phone: 18003618290
Website: https://www.credenceresearch.com/report/biologics-market
Source: MarketersMedia
Release ID: 459400
